ストックスクリーナーアプリを入手
36.35
0.41%
-0.15
前日終値:
$36.50
開ける：
$36.38
24時間の取引高:
2.94M
Relative Volume:
0.81
時価総額：
$15.71B
収益：
$2.26B
当期純損益:
$1.09B
株価収益率:
15.51
EPS:
2.3431
ネットキャッシュフロー:
$2.70B
1週間 パフォーマンス:
-3.27%
1か月 パフォーマンス:
-0.44%
6か月 パフォーマンス:
+12.33%
1年 パフォーマンス:
+32.62%
1日の値動き範囲:
$36.07
$36.60
1週間の範囲:
$35.80
$37.92
52週間の値動き範囲:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
RPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.35 | 15.78B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-16 | 開始されました | Morgan Stanley | Overweight |
| 2024-06-03 | ダウングレード | UBS | Buy → Neutral |
| 2022-06-14 | 再開されました | UBS | Buy |
| 2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-07-30 | 開始されました | Tigress Financial | Buy |
| 2020-11-09 | アップグレード | UBS | Neutral → Buy |
| 2020-07-14 | 開始されました | Evercore ISI | In-line |
| 2020-07-13 | 開始されました | BofA Securities | Buy |
| 2020-07-13 | 開始されました | Citigroup | Neutral |
| 2020-07-13 | 開始されました | Cowen | Outperform |
| 2020-07-13 | 開始されました | Goldman | Neutral |
| 2020-07-13 | 開始されました | JP Morgan | Neutral |
| 2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 開始されました | SunTrust | Buy |
| 2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Royalty Pharma PLC (NASDAQ:RPRX) Shares Purchased by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Forsta AP Fonden Decreases Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Is Royalty Pharma plc vulnerable to short sellersWeekly Investment Report & Weekly Top Stock Performers List - classian.co.kr
Vanguard Group Inc. Has $1.14 Billion Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Earnings Chart Overlay Points to Royalty Pharma plc UpsideJuly 2025 Technicals & High Yield Stock Recommendations - beatles.ru
Russell Investments Group Ltd. Has $49.64 Million Stake in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Virtu Financial LLC Has $804,000 Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Can Royalty Pharma plc expand its profit margins2025 Risk Factors & Daily Risk Controlled Trade Plans - thegnnews.com
Deutsche Bank AG Sells 1,775,038 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by Charles Schwab Investment Management Inc. - MarketBeat
Koss Olinger Consulting LLC Has $989,000 Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (RPRX) Q2 Receipts Up 20% - AOL.com
Henry Fernandez Steps Down from Royalty Pharma’s Board of Directors - citybiz
Royalty Pharma lead independent director Fernandez steps down - Investing.com
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors - The Manila Times
Cary Street Partners Financial LLC Buys Shares of 19,580 Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Henry Fernandez steps down from Royalty Pharma board - StreetInsider
Royalty Pharma's Lead Independent Director Exits Following Successful Post-IPO Growth Period - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Raised to Buy at Wall Street Zen - MarketBeat
Ex-Dividend Reminder: Eli Lilly, Teleflex and Royalty Pharma - Nasdaq
Swiss National Bank Trims Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
5 Insightful Analyst Questions From Royalty Pharma’s Q2 Earnings Call - Yahoo Finance
Is Royalty Pharma plc a potential multi baggerGlobal Markets & Fast Gaining Stock Reports - kangso.co.kr
Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT - Insider Monkey
RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments - Yahoo Finance
Royalty Pharma Director Norden Gregory Sells 33,500 Shares at $36.23 on 8/11/2025 - AInvest
CenterBook Partners LP Sells 41,728 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX) - Yahoo Finance
Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model - MSN
Did Rising Costs and Lower Margins Just Shift Royalty Pharma's (RPRX) Investment Narrative? - simplywall.st
Royalty Pharma: Keep Delivering, Buy Confirmed (NASDAQ:RPRX) - Seeking Alpha
Royalty Pharma’s Earnings Call Highlights Strong Growth and Strategic Moves - The Globe and Mail
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's Why - MarketBeat
More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream - insights.citeline.com
UBS Adjusts Price Target on Royalty Pharma to $37 From $36, Maintains Neutral Rating - MarketScreener
Royalty Pharma plc (NASDAQ:RPRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Royalty Pharma Q2 2025 Earnings: Revenue Surges to $727 Million, Exceeds Estimates - AInvest
Royalty Pharma (RPRX) Sees Revenue Rise to US$579 Million; Net Income Falls - Yahoo Finance
Royalty Pharma Reports Strong Q2 2025 Results - TipRanks
Royalty Pharma Plc Q2 Income Retreats - Nasdaq
Royalty Pharma Raises 2025 Portfolio Receipts Guidance to $3.05B-$3.15B, Achieving 20% Growth in Top Line - AInvest
Royalty Management Holding Corporation shares rise 5.65% intraday after Royalty Pharma plc reports Q2 2025 results. - AInvest
Royalty Pharma stock price target raised to $48 from $42 at BofA Securities - Investing.com UK
Royalty Pharma Q2 2025 Earnings Call Transcript - MarketBeat
Royalty Pharma (RPRX) PT Raised to $48 at BofA Securities - StreetInsider
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates - sharewise.com
Earnings call transcript: Royalty Pharma Q2 2025 shows robust growth By Investing.com - Investing.com Australia
Royalty Pharma earnings missed by $0.99, revenue fell short of estimates - Investing.com Nigeria
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
0.88%
大文字化:
|
ボリューム (24 時間):